156 related articles for article (PubMed ID: 20859436)
61. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada.
Driedger SM; Cooper E; Annable G; Brouwers M
Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619
[TBL] [Abstract][Full Text] [Related]
62. The Feasibility and Usability of a Ranking Tool to Elicit Patient Preferences for the Treatment of Trigger Finger.
Shapiro LM; Eppler SL; Kamal RN
J Hand Surg Am; 2019 Jun; 44(6):480-486.e1. PubMed ID: 30797655
[TBL] [Abstract][Full Text] [Related]
63. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
[TBL] [Abstract][Full Text] [Related]
64. Use of Simulation Modeling to Inform Decision Making for Health Care Systems and Policy in Colorectal Cancer Screening: Protocol for a Systematic Review.
Smith H; Varshoei P; Boushey R; Kuziemsky C
JMIR Res Protoc; 2020 May; 9(5):e16103. PubMed ID: 32401223
[TBL] [Abstract][Full Text] [Related]
65. Decisions about access to health care and accountability for reasonableness.
Daniels N
J Urban Health; 1999 Jun; 76(2):176-91. PubMed ID: 10924028
[TBL] [Abstract][Full Text] [Related]
66. Decision aids for people facing health treatment or screening decisions.
Stacey D; Bennett CL; Barry MJ; Col NF; Eden KB; Holmes-Rovner M; Llewellyn-Thomas H; Lyddiatt A; Légaré F; Thomson R
Cochrane Database Syst Rev; 2011 Oct; (10):CD001431. PubMed ID: 21975733
[TBL] [Abstract][Full Text] [Related]
67. Community views and perspectives on public engagement in health technology assessment decision making.
Wortley S; Tong A; Howard K
Aust Health Rev; 2017 Mar; 41(1):68-74. PubMed ID: 27050156
[TBL] [Abstract][Full Text] [Related]
68. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
[TBL] [Abstract][Full Text] [Related]
69. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
Choi Y; Navarro RP
J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
[TBL] [Abstract][Full Text] [Related]
70. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
Weekes LM; Day RO
Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
[TBL] [Abstract][Full Text] [Related]
71. Health technology funding decision-making processes around the world: the same, yet different.
Stafinski T; Menon D; Philippon DJ; McCabe C
Pharmacoeconomics; 2011 Jun; 29(6):475-95. PubMed ID: 21568357
[TBL] [Abstract][Full Text] [Related]
72. Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden.
Eckard N; Janzon M; Levin LÅ
Int J Health Policy Manag; 2014 Nov; 3(6):323-32. PubMed ID: 25396208
[TBL] [Abstract][Full Text] [Related]
73. Priority setting at the micro-, meso- and macro-levels in Canada, Norway and Uganda.
Kapiriri L; Norheim OF; Martin DK
Health Policy; 2007 Jun; 82(1):78-94. PubMed ID: 17034898
[TBL] [Abstract][Full Text] [Related]
74. Priority setting in developing countries health care institutions: the case of a Ugandan hospital.
Kapiriri L; Martin DK
BMC Health Serv Res; 2006 Oct; 6():127. PubMed ID: 17026761
[TBL] [Abstract][Full Text] [Related]
75. Patient information leaflets (PILs) for UK randomised controlled trials: a feasibility study exploring whether they contain information to support decision making about trial participation.
Gillies K; Huang W; Skea Z; Brehaut J; Cotton S
Trials; 2014 Feb; 15():62. PubMed ID: 24548781
[TBL] [Abstract][Full Text] [Related]
76. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
77. SMART Vaccines 2.0 decision-support platform: a tool to facilitate and promote priority setting for sustainable vaccination in resource-limited settings.
McCormick BJJ; Waiswa P; Nalwadda C; Sewankambo NK; Knobler SL
BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33239338
[TBL] [Abstract][Full Text] [Related]
78. The Value of Explicit, Deliberative, and Context-Specified Ethics Analysis for Health Technology Assessment: Evidence From a Novel Approach Piloted in South Africa.
Krubiner CB; Tugendhaft A; DiStefano MJ; Barsdorf NW; Merritt MW; Goldstein SJ; Mosam A; Potgieter S; Hofman KJ; Faden RR
Value Health Reg Issues; 2023 Mar; 34():23-30. PubMed ID: 36455448
[TBL] [Abstract][Full Text] [Related]
79. Ethical and Social Values for Paediatric Health Technology Assessment and Drug Policy.
Denburg AE; Giacomini M; Ungar W; Abelson J
Int J Health Policy Manag; 2022 Mar; 11(3):374-382. PubMed ID: 32801223
[TBL] [Abstract][Full Text] [Related]
80. Link between process and appraisal in coverage decisions: an analysis with structural equation modeling.
Fischer KE; Stollenwerk B; Rogowski WH
Med Decis Making; 2013 Nov; 33(8):1009-25. PubMed ID: 23771882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
